Sub therapeutic drug levels among HIV/TB co-infected patients receiving Rifampicin in northwestern Tanzania: A cross sectional clinic based studyFootnote

Peer review under responsibility of Alexandria University Faculty of Medicine.

Footnote

Available online 1 November 2016

References

• W.ManosuthiStandard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicinHIV Med952008294299
   Web of Science ®Google Scholar
• E.L.CorbettThe growing burden of tuberculosis: global trends and interactions with the HIV epidemicArch Intern Med1639200310091021
   PubMed Web of Science ®Google Scholar
• WHO, Global Tuberculosis Report; 2014.
   Google Scholar
• WHO, Interim policy on collaborative TB/HIV activities; 2004.
   Google Scholar
• WHO, Global tuberculosis control 2011, WHO., Editor; 2011.
   Google Scholar
• M.E.TorokJ.J.FarrarWhen to start antiretroviral therapy in HIV-associated tuberculosisThe New Engl J Med36516201115381540
   PubMed Web of Science ®Google Scholar
• S.D.LawnM.E.TorokR.WoodOptimum time to start antiretroviral therapy during HIV-associated opportunistic infectionsCurrent Opin Infect Diseases24120113442
   PubMed Web of Science ®Google Scholar
• G.FriedlandAdministration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIVJ Antimicrob Chemother586200612991302
   PubMed Web of Science ®Google Scholar
• M.W.BrinkhofTuberculosis after initiation of antiretroviral therapy in low-income and high-income countriesClin Infect Dis4511200715181521
   Web of Science ®Google Scholar
• A.BoulleOutcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapyJAMA30052008530539
   PubMed Web of Science ®Google Scholar
• S.D.LawnBurden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis controlAIDS2012200616051612
   PubMed Web of Science ®Google Scholar
• S.D.LawnR.WoodTuberculosis control in South Africa–will HAART help?S Afr Med J9662006502504
   Web of Science ®Google Scholar
• K.R.CollinsImpact of tuberculosis on HIV-1 replication, diversity, and disease progressionAIDS Rev432002165176
   PubMedGoogle Scholar
• C.V.FletcherConcentration-controlled compared with conventional antiretroviral therapy for HIV infectionAIDS1642002551560
   PubMed Web of Science ®Google Scholar
• H.McIlleronComplications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndromeJ Infect Dis196Suppl 12007S63S75
   PubMed Web of Science ®Google Scholar
• G.RamachandranIncreasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministrationJ Acquir Immune Defic Syndr42120063641
   Web of Science ®Google Scholar
• J.M.RaeRifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arraysJ Pharmacol Exp Ther29932001849857
   PubMed Web of Science ®Google Scholar
• D.J.PepperCombined therapy for tuberculosis and HIV-1: the challenge for drug discoveryDrug Discov Today1221–222007980989
   Web of Science ®Google Scholar
• E.RiberaRifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patientsAntimicrob Agents Chemother4511200132383241
   Web of Science ®Google Scholar
• D.B.Pedral-SampaioEfficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosisBraz J Infect Dis832004211216
   PubMedGoogle Scholar
• L.SathiaConcomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patientsAIDS Res Hum Retroviruses2472008897901
   Web of Science ®Google Scholar
• P.ClevenberghImproving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician’s point of viewCurr HIV Res242004309321
   PubMed Web of Science ®Google Scholar
• D.W.GundaPlasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western TanzaniaPLoS One892013e75118
   PubMed Web of Science ®Google Scholar
• M.DuongUsefulness of therapeutic drug monitoring of antiretrovirals in routine clinical practiceHIV Clin Trials542004216223
   PubMed Web of Science ®Google Scholar
• S.H.KhooPharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)–a randomized controlled trial of therapeutic drug monitoring and adherence supportJ Acquir Immune Defic Syndr4142006461467
   PubMed Web of Science ®Google Scholar
• F.V.LethPharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacyAIDS Res Hum Retroviruses2232006232239
   Web of Science ®Google Scholar
• Kigen G et al., Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort. PLoS One. 6(2): p. e16800.
   Google Scholar
• D.ElsherbinyPopulation pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patientsEur J Clin Pharmacol65120097180
   Web of Science ®Google Scholar
• J.J.van OosterhoutNevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult MalawiansAntivir Ther1242007515521
   Web of Science ®Google Scholar
• WHO, Treatment of tuberculosis Guidelines. 2010(WHO/HTM/TB/2009.420): p. 147.
   Google Scholar
• R.GrossbergR.GrossUse of pharmacy refill data as a measure of antiretroviral adherenceCurr HIV/AIDS Rep442007187191
   PubMedGoogle Scholar
• P.LangmannHigh-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapyJ Chromatogr B Biomed Sci Appl7551–22001151156
   Google Scholar
• COBAS®, COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, version2.0. Doc Rev. 5.0 ed., R.m. systems, Editor. 2010, Roche molecular systems USA. p. 1–30.
   Google Scholar
• G.KigenPrevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohortPLoS One622011e16800
   Web of Science ®Google Scholar
• D.G.De RequenaI.Jimenez-NacherV.SorianoChanges in nevirapine plasma concentrations over time and its relationship with liver enzyme elevationsAIDS Res Hum Retroviruses2162005555559
   Web of Science ®Google Scholar
• S.C.PiscitelliK.D.GallicanoInteractions among drugs for HIV and opportunistic infectionsN Engl J Med344132001984996
   PubMed Web of Science ®Google Scholar
• J.BertrandDependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in CambodiaJ Infect Dis20932014399408
   PubMed Web of Science ®Google Scholar
• K.CohenEffect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South AfricaAntivir Ther1452009687695
   PubMed Web of Science ®Google Scholar
• J.BertrandMultiple genetic variants predict steady-state nevirapine clearance in HIV-infected CambodiansPharmacogenet Genomics22122012868876
   PubMed Web of Science ®Google Scholar
• P.S.RiskaBiotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzeesDrug Metab Dispos2712199914341447
   Web of Science ®Google Scholar
• A.PatelSafety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1J Acquir Immune Defic Syndr371200411661169
   Web of Science ®Google Scholar
• N.B.BhattNevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationshipJ Antimicrob Chemother7012015225232
   Web of Science ®Google Scholar
• R.S.CvetkovicK.L.GoaLopinavir/ritonavir: a review of its use in the management of HIV infectionDrugs6382003769802
   PubMed Web of Science ®Google Scholar
• V.OldfieldG.L.PloskerLopinavir/ritonavir: a review of its use in the management of HIV infectionDrugs669200612751299
   PubMed Web of Science ®Google Scholar
• R.A.MurphyCoadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South AfricaPLoS One792012e44793
   Web of Science ®Google Scholar
• H.SunpathDouble-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South AfricaInt J Tuberc Lung Dis1862014689693
   Web of Science ®Google Scholar
• E.T.OgburnEfavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylationDrug Metab Dispos387201012181229
   PubMed Web of Science ®Google Scholar
• P.RiskaDisposition and biotransformation of the antiretroviral drug nevirapine in humansDrug Metab Dispos2781999895901
   PubMed Web of Science ®Google Scholar
• T.N.GengiahThe influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosisEur J Clin Pharmacol6852012689695
   PubMed Web of Science ®Google Scholar
• A.F.LuetkemeyerRelationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE StudyClin Infect Dis5742013586593
   PubMed Web of Science ®Google Scholar
• S.UttayamakulEffects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adultsAIDS Res Ther720108
   PubMed Web of Science ®Google Scholar
• P.ArnaldoFrequencies of cytochrome P450 2B6 and 2C8 allelic variants in the mozambican populationMalays J Med Sci20420131323
   PubMedGoogle Scholar
• C.S.AlexanderAntiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced diseaseJ Infect Dis18842003541548
   Web of Science ®Google Scholar
• L.AhouaRisk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern UgandaBMC Infect Dis9200981
   PubMed Web of Science ®Google Scholar
• W.ManosuthiA randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R StudyClin Infect Dis4812200917521759
   PubMed Web of Science ®Google Scholar
• B.S.KappelhoffNevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN studyAntivir Ther1012005145155
   PubMed Web of Science ®Google Scholar
• A.I.VeldkampHigh exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individualsAIDS159200110891095
   PubMed Web of Science ®Google Scholar
• R.GieschkeRelationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patientsClin Pharmacokinet37119997586
   PubMed Web of Science ®Google Scholar
• D.M.BurgerLow plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapyAntivir Ther341998215220
   Web of Science ®Google Scholar
• K.C.SigaloffUnnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in AfricaJ Acquir Immune Defic Syndr58120112331
   PubMed Web of Science ®Google Scholar
• A.JohannessenVirological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural TanzaniaBMC Infect Dis92009108
   Web of Science ®Google Scholar